Ekong E. Udoh  
Blessing N. Nwazuluoke  
Victor E. Bassey  
Olugbemi O. Motilewa  
Regina I. Ejemot-Nwadiaro  
Martin M. Meremikwu

Effectiveness and tolerability of standardized milk based, standardized non-milk based and hospital-based formulations in the management of moderate acute malnutrition in under-five children: A randomized clinical trial

Abstract: Introduction  
Moderate acute malnutrition (MAM) is a leading cause of under-five morbidity and mortality globally. Supplementary feeding is a strategy recommended by WHO for managing the condition.  
Objective: To evaluate the effectiveness and tolerability of standardized milk-based formulation (SMBF), standardized non-milk based formulation (SNMBF) and hospital-based formulation (HBF) in under-fives with MAM.  
Method: This was an open label randomized clinical trial in which eligible children aged 6 – 59 months with MAM were assigned to receive the SMBF, SNMBF or HBF at 50% of their daily caloric requirement with their regular family diet for four months. Their baseline characteristics and anthropometric indices were noted. They were followed up on two weekly basis during which further assessments were performed. The analysis for effectiveness and tolerability of the formulations were based on “per protocol”.  
Results: A total of 687 children were screened and 188 enrolled. Seventy children received SMBF, 63 received SNMBF while 55 received HBF. There were 54/70 (77.1%), 57/64 (89.1%) and 46/55 (83.6%) evaluable participants in the SMBF, SNMBF and HBF group respectively. Recovery from MAM was 43/54 (79.6%), 40/57 (70.2%) and 32/46 (69.6%) in the SMBF, SNMBF and HBF group respectively. Normal nutritional status was attained by 13 (24.0%), 10 (17.6%) and 5 (10.9%) children in the SMBF, SNMBF and HBF group respectively. Diarrhea and skin rashes were the main features of poor tolerability.  
Conclusions: The formulations were effective in managing MAM in childhood but the SMBF was the most effective. Diarrhea and skin rashes were the main features of poor tolerability.  
Keyword: nutrition, formulations, follow up, malnutrition, under-fives

Introduction  
Moderate acute malnutrition (MAM) is presently a leading cause of childhood morbidity and mortality globally. About 33 million under-fives residing in South Asia, West and Central Africa are moderately malnourished. The condition accounts for about 70.0% of all under-five malnutrition-related deaths globally. The condition is managed by supplementary feeding using pre-packaged, energy-dense nutritional formulations along with dietary counselling. Ready-to-use supplementary foods (RUSFs) deployed in this condition are known to effective in improving the nutritional status of malnourished children. The RUSFs are often supplied on programmatic basis by donor agencies and as such, not readily available in settings where childhood malnutrition is endemic. The non-availability of...
Effectiveness and tolerability of standardized milk based, standardized non-milk based and hospital-based formulations in the management of moderate acute malnutrition in under-five children: a randomized clinical trial Ekong E. Udoh et al

these formulations in regions where childhood malnutrition is endemic constitutes a major barrier to the achievement of 40% reduction of childhood stunting and the reduction of childhood wasting to less than 5% as contained in the WHO global nutrition targets of 2025. In settings where childhood malnutrition is prevalent and RUSFs are not readily available, WHO recommends the use of nutrient dense formulations prepared from locally available food stuffs as well as the evaluation of the effectiveness of the formulations. Though improvement in nutritional status has been observed among under-fives with MAM following the use of formulations prepared from locally available food stuffs, there is paucity of empirical data on their effectiveness. The management of MAM in childhood is still evolving and there is presently no global consensus on the most appropriate dietary formulation for treating under-fives with the condition. It is therefore necessary to evaluate the effectiveness of locally available nutritional formulations with the potential for managing MAM in a given setting.

The standardized milk-based formulation (SMBF), the standardized non-milk based formulation (SNMBF) and the hospital-based formulation (HBF) are examples of nutritional formulations in the country with potentials for managing MAM in childhood. The SMBF and SNMBF are commercially prepared while the HBF is prepared by the hospital dieticians. The formulations all have maize as the main source of carbohydrate while protein is mainly from milk for the SMBF, soyabean for the SNMBF and a combination of milk and soybeans in the HBF. Data on the effectiveness and tolerability of these formulations are needed for evidence-based decision in the management of under-fives with MAM in the country.

Objective

To compare the effectiveness and tolerability of SMBF, SNMBF and HBF in the management of children aged 6–59 months with MAM.

Outcome measures

Primary: improvement from moderate to mild malnutrition/normal nutritional status (weight-for-height Z-score of +1 to -2 SD) and non-recovery/deterioration to severe acute malnutrition (weight-for-height Z-score between -2 and -3 SD/Z score <-3 SD).

Secondary: tolerability (occurrence of gastrointestinal and extra-intestinal adverse events).

Sample size calculation

This was calculated based on non-inferiority of the SMBF/SNMBF compared to the HBF. Using 80% certainty that the lower limit of a 95% two-sided confidence interval will be above the non-inferiority limit of 0.3 assuming a standard deviation of 0.55 units. The minimum sample size obtained was 48 children per group. To make for 10% attrition, the minimum sample size was increased to 53 children per study arm.

Study population

Children aged 6 to 59 months with MAM residing in the selected LGAs. The case definition of MAM was based on weight-for-height/length Z-score between -2 and -3 SD or mid upper arm circumference (MUAC) of 11.5 cm to 12.5 cm in the absence of oedema.

Eligibility criteria

Children aged 6–59 months that met the case definition of MAM were included following parental consent. Those with chronic illnesses (cardiac disease, renal disease, tuberculosis, liver disease or HIV/AIDS), feeding difficulties (gastroesophageal reflux diseases or cleft palate), neurologic disease (cerebral palsy) and diarrheal illnesses were excluded.

Randomization

Balloting technique was used to randomize the participants to the different interventions based on the study sites. The randomization process was implemented by non-members of the research team. Participants enrolled in PHC Adadiah received the SMBF; those enrolled in PHC Okopedi used received the SNMBF while those enrolled in PHC MbaekEtoi received the HBF.

Participant assessment

The basic demographic and clinical information of the children were obtained from their caregivers using a
Effectiveness and tolerability of standardized milk based, standardized non-milk based and hospital-based formulations in the management of moderate acute malnutrition in under-five children: a randomized clinical trial Ekong E. Udoh et al

structured questionnaire. A general physical examination and systemic examination were done. Their anthropometry (weight, MUAC and length/height) was measured using standard techniques.\textsuperscript{12}

Investigational products

The investigational products were; the SMBF, SNMBF and HBF.

1) The SMBF was a pre-packaged formulation produced by a reputable food company. The formulation consisted of carbohydrates (mainly maize), proteins (mainly dairy milk), fats, minerals and vitamins. It contained 205 kcal/50g in a 50g sachet.

2) The SNMBF was also produced by a reputable food company. It consisted of carbohydrates (maize), proteins (soya bean), fats, minerals and vitamins. It was contained in 400g tins which had 199 kcal/50g.

3) The HBF was formulated by the hospital dietician. It consisted of carbohydrates (mainly from maize), proteins (soybean and dairy milk), fats, vitamin B complex, vitamin C and iron. It was a loose formulation that had 215 kcal/50g. The composition of the formulations is presented in Appendix 1. They were stored at optimal temperature and humidity. The batch number, manufactory and expiry dates of the standardized formulations were verified before being used.

Dietary counselling and food demonstration exercise

The caregivers were counselled on exclusive breast feeding for six months and continuation of breast feeding up to two years age. They were also counselled complementary food preparation using locally available food stuffs, appropriate feeding practice and hand hygiene. Food demonstration exercises using the investigational products with hands-on sessions for the caregivers were conducted.

Administration of investigational products

Each child received an amount of formulation equivalent to 50\% of his/her daily caloric requirement based on the intervention arm of his/her assignment along with the regular family diet. Children aged 6–24 months received 100 kcal/kg/day of the formulation assigned to them while those aged 25 – 59 months received 90 kcal/kg/day. The formulations were supplied every two weeks to the caregivers at the health facilities for four months. Those 6–23 months were fed thrice daily with the formulations in addition to breast feeding while those 24–59 months were fed twice daily. The caregivers were instructed not to share the formulations with other members of the household. They were requested to present empty sachets of the formulations which were used as proxies for monitoring adherence to dietary regimen during their biweekly facility visit. They were instructed to note/record unusual gastrointestinal events like vomiting, diarrhea (the passage of ≥ 3 loose stools in 24 hours), abdominal discomfort, constipation, and regurgitation as well as extra-intestinal events during the study period.

Follow-up of participants

The participants were followed up on two weekly basis for four months during which clinical assessment, anthropometric measurement, food demonstration exercise with hands-on sessions were performed. The feeding practices of the caregivers and adverse events of the formulations were noted. Children that developed mild illnesses were treated appropriately by the research team in the community while those with severe illnesses were treated in the UUTH after obtaining the caregiver’s consent.

Ethics

Approval for the conduct of the study was obtained from the Health Research Ethics Committee of UUTH and the community chiefs. Parental consent was obtained in writing before inclusion of any eligible child into the study. The trial was registered with the Pan African Clinical Trial Registry with a trial registration number of PACTR201704002119141.

Statistics

Data was analyzed using Stata. Weight-for-height z-score was determined based on the National Center for Disease Statistics, 2000 growth curves. The characteristics of the children were described using frequency and percentage for categorical variables and means with standard deviation for continuous variables. Categorical variables were compared using Pearson’s chi-square test ($\chi^2$) while the means of continuous variables were compared using ANOVA. The effectiveness and tolerability of the formulations were determined based on ‘per-protocol’ analysis. Sub-group analysis based on age group was also performed. Statistical tests were deemed significant if p-value was < 0.05.

Results

A total of 687 children were screened and 189 enrolled. Seventy children were assigned to the SMBF but 54/70 (77.1\%) completed the study, 64 were assigned to the SNMBF but 57/64 (89.1\%) completed the study while 55 were assigned to the HBF but 46/55 (83.6\%) completed the study. Fifteen children were withdrawn due to protocol violation while 17 were lost to follow up (Figure 1).

1. Baseline characteristics of study participants

The demographic and anthropometric parameters of the
Effectiveness and tolerability of standardized milk based, standardized non-milk based and hospital-based formulations in the management of moderate acute malnutrition in under-five children: a randomized clinical trial Ekong E. Udoh et al

Table 1: Baseline clinical characteristics of study participants

| Characteristics of participants | Milk based formulation | Non-milk based formulation | Hospital-based formulation | P value |
|--------------------------------|------------------------|---------------------------|---------------------------|---------|
| Gender                         |                        |                           |                           |         |
| Male                           | 38                     | 22                        | 25                        |         |
| Female                         | 32                     | 42                        | 30                        |         |
| Mean age (months)              | 17.1 ±10.86            | 22.6±14.56                | 19.09± 11.60              | 0.1616  |
| Mean weight (Kg)               | 7.80±2.01              | 8.14±2.10                 | 8.12 ± 1.96               | 0.6723  |
| Mean height/length (cm)        | 76.15 ± 9.88           | 77.3 ± 9.99               | 76.88±10.07               | 0.8442  |
| MUAC (cm)                      | 12.29±1.09             | 12.27±0.78                | 12.45 ± 0.90              | 0.306   |

MUAC = Mid Upper Arm Circumference

2. Effect of standardized milk-based compared to hospital-based formulation on MAM

The recovery from moderate acute malnutrition (MAM) for all age categories was 79.6% (43/54) in the children treated with the SMBF as against 69.6% (32/46) in those treated with the HBF as seen in Table 2. There was a higher recovery with the SMBF compared to the HBF in the age categories of 6 – 23 months and 24 – 59 months as displayed in Table 2.

Table 2: Effect of Milk based formulation compared to Hospital-based formulation on MAM

| Outcome                                      | Milk based formulation | Hospital-based formulation | Test for significance |
|----------------------------------------------|------------------------|---------------------------|-----------------------|
| All Under-fives (6-59 months)                | N=54                   | N=46                      | χ² = 1.3419           |
| Recovery from MAM                            | 43 (79.6%)             | 32 (69.6%)                | p = 0.2466            |
| No improvement or worse                      | 11 (20.1%)             | 14 (30.4%)                | RR=1.14(0.91-1.45)    |
| Infants and young children (6-23 months)     | N=42                   | N=33                      |                       |
| Recovery from MAM                            | 34 (80.9%)             | 25 (75.7%)                | χ² = 0.2972           |
| No improvement or worse                      | 8 (19.1%)              | 8 (24.3%)                 | p = 0.5881            |
| Children aged 24 -59 months                  | N = 12                 | N = 13                    | RR=1.07(0.84-1.36)    |
| Recovery from MAM                            | 9 (75.0%)              | 7 (53.8%)                 | *F= 0.411             |
| No improvement or worse                      | 3 (25.0%)              | 6 (46.2%)                 | RR = 1.39 (0.76-2.54) |

MAM = Moderate acute malnutrition

3. Effect of standardized non milk based compared to hospital-based formulation on MAM

The recovery from MAM for all age categories treated with the SNMBF was 70.2% (40/50) as against 69.6% (32/46) in the HBF group. In infants and young children, the recovery from MAM was higher with the HBF than SNMBF while the converse was the case in those 24 – 59 months as shown in Table 3.

Table 3: Effect of standardized non-milk based formulation compared to hospital-based formulation on MAM

| Outcome                                      | Standardized Non-Milk based formulation | Hospital-based formulation | Test for significance |
|----------------------------------------------|----------------------------------------|---------------------------|-----------------------|
| All Under-fives (6-59 months)                | N=57                                   | N=46                      | χ² = 0.0045           |
| Recovery from MAM                            | 40 (70.2%)                             | 32 (69.6%)                | p = 0.9464            |
| No improvement or worse                      | 17 (29.8%)                             | 14 (30.4%)                | RR=1.52(0.97-2.38)    |
| Infants and young children (6-23 months)     | N=37                                   | N=33                      |                       |
| Recovery from MAM                            | 25 (67.6%)                             | 25 (75.7%)                | χ² = 0.5733           |
| No improvement or worse                      | 12 (32.4%)                             | 8 (24.3%)                 | p = 0.4489            |
| Children aged 24 –59 months                  | N = 20                                 | N = 13                    | RR=0.89 (0.66-1.20)   |
| Recovery from MAM                            | 15 (75.0%)                             | 7 (53.8%)                 | F = 0.269             |
| No improvement or worse                      | 5 (25.0%)                              | 6 (56.2%)                 | RR=1.39 (0.79-2.45)   |

MAM = Moderate acute malnutrition
Effectiveness and tolerability of standardized milk based, standardized non-milk based and hospital-based formulations in the management of moderate acute malnutrition in under-five children: a randomized clinical trial
Ekong E. Udoh et al

Fig 1: Flow diagram of study profile

4. Effect of nutritional formulations on full catch-up growth of study participants

The overall recovery from MAM was 73.2% (115/157). Full catch-up growth was observed in 17.8% (28/157) of the participants. Recovery from MAM with catch-up growth was highest among those that received the SMBF, 24.0% (13/54) and least 10.9% (5/54) in those that received the HBF. The difference in proportion of full catch-up growth in the various groups was not statistically significant ($\chi^2 = 2.961; p = 0.228$) as shown in Table 4.

Table 4: Attainment of full catch-up growth based on nutritional formulation

| Nutritional intervention group | Attainment of full catch-up growth |
|-------------------------------|-----------------------------------|
| Standardized milk-based formulation (N = 54) | 13 (24.0%) |
| Standardized non-milk-based formulation (N = 57) | 10 (17.6%) |
| Hospital-based formulation (N = 46) | 5 (10.9%) |

Full catch-up growth: weight-for-height Z-score of +1 to -1 SD

The main features of poor tolerability were diarrhea and report of skin reaction. The occurrence of diarrhea was comparable in the different groups ($\chi^2 = 0.169; p = 0.918$). The report of skin reaction was highest (16.7%) in the SMBF group and lowest (2.2%) in the HBF group.

Table 5: Tolerability of formulations among study participants

| Features of tolerability | Milk-based formulation 54 | Non-milk based formulation 57 | Hospital-based formulation 46 |
|--------------------------|---------------------------|-------------------------------|------------------------------|
| Diarrhoea                | 6 (11.1%)                 | 6 (10.5%)                     | 4 (8.7%)                     |
| Regurgitation            | 0 (0%)                    | 4 (7.0%)                      | 0 (0%)                       |
| Vomiting                 | 1 (1.9%)                  | 1 (1.8%)                      | 1 (2.2%)                     |
| Abdominal colic          | 2 (3.7%)                  | 0 (0.0%)                      | 0 (0%)                       |
| Skin rash                | 9 (16.7%)                 | 3 (5.3%)                      | 1 (2.2%)                     |

Discussion

The effectiveness of standardized milk-based formulation (SMBF), standardized non-milk based formulation (SNMBF) and hospital-based formulation (HBF) at 50%
of the daily caloric requirement of under-five children with moderate acute malnutrition (MAM) while on their regular family diet for four months was 79.6%, 70.2% and 69.6% respectively. The effectiveness of the SMBF on MAM in this study is similar to the 80.0% and 79.1% reported by Matilksy et al\textsuperscript{13} in Malawi and Nacker et al\textsuperscript{14} in Niger but slightly higher than 73.0% reported in Ethiopia by Karakochuk et al\textsuperscript{15} among a similar category of children treated with a Lipid Nutrient Supplement (LNS). The effectiveness of the different nutritional formulations in this study is lower than the 85% reported by Medoua et al\textsuperscript{16} in Cameroun among children aged 25 – 59 months that were treated for two months with a LNS but comparable to 73.0% recovery reported in those treated with a Corn Soy Blend. The difference in recovery from MAM between participants in this study and that of Medoua et al\textsuperscript{16} could be attributed to the difference in the type of formulations used for feeding the children. Lipid-containing formulations are likely to provide more energy that would positively impact on growth and recovery from malnutrition when compared to formulations without lipids.

The variation in the protein source and micronutrient content of the formulations might also have influenced the outcome of this study. The SMBF contained milk (animal protein) which is usually of high biological value, the SNMBF contained soybeans (plant protein) which is usually deficient in one or more of the indispensable amino acids while the HBF contained milk and soybeans (combination of animal and plant protein). Adequate intake of protein of high biological value (animal protein) is recommended for actively growing children.\textsuperscript{17} Thus, the highest recovery from MAM was expected in children treated with the SMBF and the least in those treated with SNMBF. As expected, those treated with the SMBF had the highest recovery but contrary to our expectation, there was no difference in recovery between the HBF and SNMBF groups. The relatively high concentration of micronutrients (calcium, vitamin D and zinc) in the standardized formulation (SMBF/ SNMBF) compared to the HBF might have contributed to this finding. Calcium and vitamin D are important for skeletal growth while zinc is known to improve growth and immunologic function.\textsuperscript{18} Hence, children that received the SMBF or SNMBF were more likely to improve in linear growth than those that received the HBF.\textsuperscript{18} The positive impact of protein source on recovery in the HBF group versus the SNMBF group might have been equilibrated by the relatively high micronutrient composition of the SNMBF when compared to the HBF resulting in no detectable difference in effectiveness between both formulations.

Another possible reason for the lack of detectable difference in effectiveness between the HBF and SNMBF is the duration of the study. An appreciable change in the axial growth but not linear growth could be observed within a period of four months in clinical trials evaluating nutritional formulations for malnourished children.\textsuperscript{19} However, to appreciate the effect of nutritional formulations on linear growth, an intervention period much longer than four months is required. Some studies that detected significant difference in effect of formulations on linear growth were conducted for six months and beyond.\textsuperscript{10} Besides, the appreciable overall recovery from MAM in the different groups; a small proportion of children in each group achieved full catch-up growth with the SMBF group having the highest (24.0%). Intervention in childhood nutrition within the first 1000 days is known to be quite critical to the attainment of the full catch-up growth and development potential of children. This period is recognized as a window of opportunity for instituting targeted interventions aimed at preventing or reversing nutritional deficiencies and functional impairments in young children.\textsuperscript{20} The attainment of full catch-up growth in children with MAM reduces the risk of relapse to MAM in settings of persistent household food insecurity when compared to those that attain a modest recovery from MAM without achieving full catch-up growth within the intervention period.\textsuperscript{21} Full catch-up growth does not only impact on the physical growth parameters and nutritional status of children but also impacts positively on their immunologic, metabolic and cognitive functions.\textsuperscript{1}

The main features of poor tolerability of the formulations were diarrhea which occurred in a similar frequency across the three intervention arms and skin rash which was reported mainly in the SMBF group. The incidence of vomiting was also similar in the different groups. Cochrane systematic reviews that evaluated the effect of LNS and CSB in the management of under-fives with MAM reported similar occurrence of diarrhea in both groups with the use of LNS and CSB but a higher frequency of vomiting among those managed with LNS than those managed with CSB.\textsuperscript{3,22} In view of the nutritional crisis of children residing in low-/middle income countries, the increasing burden of MAM and the several life-threatening complications associated with the condition, large-scale community-based supplementary feeding of under-five children with MAM using any of the evaluated formulations in this study will go a long way to enhance their recovery thereby reducing childhood mortality in the region. Further research at bridging the existing micronutrient gap regarding linear growth in the HBF is needed to optimize its effect.

This study provides evidence on the effectiveness and tolerability of some of the locally available nutritional formulations for managing MAM in under-fives in the country. Large scale studies are needed not only to confirm this but to also to thoroughly investigate the observed adverse events of the formulations.
Conclusions

The use of SMBF, SNMBF or HBF at 50% of the daily caloric requirements of children aged 6 – 59 months with MAM was quite effective in managing the condition. The highest recovery from MAM and attainment of full catch-up growth was observed in those treated with the SMBF, while the SNMBF and HBF were of comparable effectiveness. The main features of poor tolerability were diarrhea and skin rashes. Any of these formulations could be deployed for large scale use in regions where MAM in childhood is endemic.

Acknowledgements

We deeply appreciate the Management of UUTH and members of Paediatrics Department, UUTH for accepting to host this project. Our special thanks go to Dr. Frances Okpokowuruk and Dr. Mkpouto Akpan who headed the department during the study period and doubled as internal monitors of the project. We also thank members of the research team, the matrons of the selected PHCs, the community leaders and caregivers of the enrolled children for their co-operation. We are truly grateful to Dr. Chioma Emma-Nwachukwu of Nestle Nutrition Institute, Africa (NNIA) for her commitment to the success of the project. Finally, our utmost gratitude goes to God Almighty for safety and preservation during the study period.

Authors Contributions

The study was conceived by Ekong Udoh and supervised by Martin Meremikwu, Ekong Udoh, Blessing Nwazulueko, Victor Bassey, Regina Ejemot-Nwadiaro and Martin Meremikwu prepared the protocol, study design and data collection tools. Blessing Nwazulueko, Victor Bassey, OlugbemiMotilewa and Ekong Udoh collected the data which was analyzed by OlugbemiMotilewa, Regina Ejemot-Nwadiaro, Ekong Udoh and Martin Meremikwu. Data interpretation was done by Martin Meremikwu, Blessing Nwazulueko, Victor Bassey, OlugbemiMotilewa and Ekong Udoh. All the authors contributed to the write up of manuscript and approved the final version.

Conflict of interests: None

Funding: The study was funded by Nestle Nutrition Institute Africa (NNIA). NNIA also provided the standardized milk based and the standardized non milk based formulations used in the study. However, NNIA did not influence the design, conduct, analysis, interpretation and the reporting of the study.

References

1. Martorell R. The nature of child malnutrition and its long-term implication. Food and Nutrition Bulletin 1999; 20 (3): 288 – 292.
2. Regina A, Patrick W, Rebecca B. Management of Moderate Acute Malnutrition: Current Knowledge and Practice. CMAM Forum Technical Brief. 2014. p. 1-38.
3. WHO: Guidelines for inpatient treatment of severely malnourished children. WHO, Geneva; 2003: 150.
4. Wagh VD, Deore BR. Ready to Use Therapeutic Food: An Overview. Advances in life sciences and health 2015; 2 (1): 1 – 15.
5. Lazzarini M, Rubert L, Pani P. Specially formulated foods for treating children with moderate acute malnutrition in low- and middle-income countries (Review). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD009584. DOI: 10.1002/14651858. CD009584.
6. WHO: WHO, UNICEF, WFP and UNHCR consultation on the programmatic aspects of the management of moderate acute malnutrition in children under five years of age WHO, Geneva. 2010: 1-18.
7. WHO. Global nutrition targets 2025: policy briefseries (WHO/ NMH/NHD/14.2). Geneva: World Health Organization; 2014: 1-2.
8. WHO: Meeting on the dietary management of Moderate Acute Malnutrition 30 September to 3 October 2008. Food and Nutrition Bulletin 2009; 30 (3): 1 – 264.
9. Annan RA, Webb P, Brown R. Management of Moderate Acute Malnutrition: Current knowledge and practice. Community-based management of acute malnutrition forum technical brief. 2014. p. 1 – 39.
10. Lenters, L.M., Wazny, K., Webb, P. Tahmeed A, Zulfiqar AB. Treatment of severe and moderate acute malnutrition in low- and middle-income settings: a systematic review, meta-analysis and Delphi process. BMC Public Health 2013; 13: S3-S23.
11. Martha Anker. Calculation of required sample size. In: Beaglehole R, Bonita R (eds). Basic Epidemiology. WHO, Geneva 1993; 413 – 428.
12. Fengan L, Lynne RW, Rachel N, Marie KF. Anthro- pometric measurement standardization in the US – affiliated Pacific: Report from the children’s healthy living program. Am J Hum Biol. 2016; 28(3): 364-371.
13. Matilksy DK, Maleta K, Castleman T, Manary MJ. Supplementary feeding with fortified spreads results in higher recovery rates than with a corn/soy blend in moderately wasted children. *J Nutrition* 2009; 139: 773 – 8.

14. Nackers F, Broillet F, Oumarou D, Djibo A, Gaboulaud V, Guerin PJ, Rusch B, Grais RF, Captopi V. Effectiveness of ready-to-use therapeutic food compared to a corn/soy-blend-based pre-mix for the treatment of childhood moderate acute malnutrition in Niger. *J Tropical Pediatrics* 2010; 56 (6): 407 – 13.

15. Karakochuk C, van den Briel T, Stephens D, Zlotkin S. Treatment of moderate acute malnutrition with ready-to-use supplementary food resulted in higher overall recovery rates compared with a corn-soya blend in children in Southern Ethiopia: an operations research trial. *Am J Clin Nutr* 2012; 96: 911 - 6.

16. Medoua GN, Ntsama PM, Ndzaana CA, Essa’a VJ, Tsafack JT, Dimodi HT. Recovery rate of children with moderate acute malnutrition treated with ready-to-use supplementary food (RUSF) or improved corn-soya blend (CSB+): a randomized controlled trial. *Public Health Nutrition* 2016; 19(2): 363-70.

17. Joannes BV. Protein. In: B. Koletzko (ed). Pediatric Nutrition in Practice. 2nd edn. Vervey (Switzerland): S. Karger, 2015; 41-45.

18. Michael HG. Proposed recommended nutrient densities for moderately malnourished children. *Food and Nutrition Bulletin*. 2009: 267-342.

19. Rondo Schilling P. Supplementary feeding programs: a critical analysis. *Rev. Saude Public.*, S. Paulo, 1990; 24(5): 412-9.

20. Cameron N. The biology of growth. In: Barker DJ, Bergmann R, Ogra PL, editors. Nestle Nutrition Workshop Series Pediatric Program Volume 61 - the window of opportunity. Switzerland: *Les Presses de la Venoge S.A.*; 2007. p. 1-5.

21. Indi T, Somalee M, Ellen M, Kelsey R, Chrissie T, Kenneth M, Mark JM. Extending supplementary feeding for children under five with moderate acute malnutrition leads to lower relapse rate. *J Pediatr Gastroenterol Nutr*. 2015; 60 (4): 544 - 549.

22. Gera T, Pena-Rosas JP, Boy-Mena E, Sachdev HS. Lipid based nutrient supplements (LNS) for treatment of children (6months to 59 months) with moderate acute malnutrition (MAM): A systematic review. *PLoS ONE* 2017;12 (9): e0182096.

---

### Appendix 1: Comparison of nutrient composition of the different formulations

| Average Nutrient Composition (unit) | Cereal-based formulation (Standardized milk-based formulation) | Soya-Cereal based formulation (Standardized non-milk based formulation) | Hospital-based formulation |
|------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------|
| Energy (Kcal)                      | Per meal (50g=200ml) % RDA                                  | Per meal (50g=200ml) % RDA                                  | Per meal 200ml % RDA      |
| Fat (gm)                           | 5                                                             | 4.5                                                           | 10.7                      |
| Linoleic acid (gm)                 | 0.75                                                          | 1.7                                                           | 1.89                      |
| Protein (gm)                       | 7.5                                                           | 7.5                                                           | 7.2                       |
| Carbohydrate (gm)                  | 32.5                                                          | 32.1                                                          | 22.08                     |
| Dietary fibre (mg)                 | 2.15                                                          | 3.5                                                           | 0.15                      |
| Vit. A (IU)                        | 650                                                           | 750                                                           | 555                       |
| Vit. D (IU)                        | 100                                                           | 100                                                           | 40                        |
| Vit. E (IU)                        | 3.4                                                           | 3.4                                                           | 1.97                      |
| Vit. C (mg)                        | 25                                                            | 25                                                            | 43.6                      |
| Vit. B1 (mg)                       | 0.3                                                           | 0.4                                                           | 0.421                     |
| Vit. B2 (mg)                       | 0.37                                                          | 0.4                                                           | 0.602                     |
| Niacin (mg)                        | 1.5                                                           | 2.0                                                           | 4.78                      |
| Vit. B6 (mg)                       | 0.5                                                           | 0.15                                                          | 0.031                     |
| Folic Acid (µg)                    | 20                                                            | 40.0                                                          | 41.0                      |
| Vit. B12 (µg)                      | 0.55                                                          | 0.4                                                           | 0.32                      |
| Calcium (mg)                       | 300                                                           | 195                                                           | 128.79                    |
| Sodium (mg)                        | 72.5                                                          | 105                                                           | 48.7                      |
| Iron (mg)                          | 3.8                                                           | 5.0                                                           | 3.23                      |
| Zinc (mg)                          | 3.0                                                           | 3.0                                                           | 0.384                     |

**% RDA:** Percentage of Recommended Dietary Allowance.